دورية أكاديمية

The M1/M2 spectrum and plasticity of malignant pleural effusion-macrophage in advanced lung cancer.

التفاصيل البيبلوغرافية
العنوان: The M1/M2 spectrum and plasticity of malignant pleural effusion-macrophage in advanced lung cancer.
المؤلفون: Wu, Ming-Fang, Lin, Chih-An, Yuan, Tzu-Hang, Yeh, Hsiang-Yuan, Su, Sheng-Fang, Guo, Chin-Lin, Chang, Gee-Chen, Li, Ker-Chau, Ho, Chao-Chi, Chen, Huei-Wen
المصدر: Cancer Immunology, Immunotherapy; May2021, Vol. 70 Issue 5, p1435-1450, 16p
مصطلحات موضوعية: LUNG cancer, CANCER patients, PLEURAL effusions, PROGRAMMED death-ligand 1, LUNGS, MACROPHAGES
مستخلص: Background: Malignant pleural effusion (MPE)-macrophage (Mφ) of lung cancer patients within unique M1/M2 spectrum showed plasticity in M1–M2 transition. The M1/M2 features of MPE-Mφ and their significance to patient outcomes need to be clarified; furthermore, whether M1-repolarization could benefit treatment remains unclear. Methods: Total 147 stage-IV lung adenocarcinoma patients undergoing MPE drainage were enrolled for profiling and validation of their M1/M2 spectrum. In addition, the MPE-Mφ signature on overall patient survival was analyzed. The impact of the M1-polarization strategy of patient-derived MPE-Mφ on anti-cancer activity was examined. Results: We found that MPE-Mφ expressed both traditional M1 (HLA-DRA) and M2 (CD163) markers and showed a wide range of M1/M2 spectrum. Most of the MPE-Mφ displayed diverse PD-L1 expression patterns, while the low PD-L1 expression group was correlated with higher levels of IL-10. Among these markers, we identified a novel two-gene MPE-Mφ signature, IL-1β and TGF-β1, representing the M1/M2 tendency, which showed a strong predictive power in patient outcomes in our MPE-Mφ patient cohort (N = 60, p = 0.013) and The Cancer Genome Atlas Lung Adenocarcinoma dataset (N = 478, p < 0.0001). Significantly, β-glucan worked synergistically with IFN-γ to reverse the risk signature by repolarizing the MPE-Mφ toward the M1 pattern, enhancing anti-cancer activity. Conclusions: We identified MPE-Mφ on the M1/M2 spectrum and plasticity and described a two-gene M1/M2 signature that could predict the outcome of late-stage lung cancer patients. In addition, we found that "re-education" of these MPE-Mφ toward anti-cancer M1 macrophages using clinically applicable strategies may overcome tumor immune escape and benefit anti-cancer therapies. [ABSTRACT FROM AUTHOR]
Copyright of Cancer Immunology, Immunotherapy is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
قاعدة البيانات: Complementary Index
الوصف
تدمد:03407004
DOI:10.1007/s00262-020-02781-8